Tango Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
TNGX$24.30+6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| AccumulatedOther | ||||||
|---|---|---|---|---|---|---|
| Common Stock Outstanding · Additional · Comprehensive · Total | ||||||
| Shares | Amount | Paid-inCapital | Income(Loss) | AccumulatedDeficit | Stockholders’Equity | |
| Balance at December 31, 2021 | 87,598,184 | 88 | 506,760 | (765) | (161,336) | 344,747 |
| Issuance of common stock from exercise of options and employee stock purchase plan | 581,190 | — | 1,623 | — | — | 1,623 |
| Stock based compensation expense | — | — | 14,230 | — | — | 14,230 |
| Business combination and PIPE financing, issuance costs | — | — | (8) | — | — | (8) |
| Other comprehensive loss | — | — | — | (2,940) | — | (2,940) |
| Net loss | — | — | — | — | (108,176) | (108,176) |
| Balance at December 31, 2022 | 88,179,374 | $88 | $522,605 | $(3,705) | $(269,512) | $249,476 |
| Issuance of common stock from exercise of options and employee stock purchase plan | 826,714 | — | 1,941 | — | — | 1,941 |
| Stock based compensation expense | — | — | 19,079 | — | — | 19,079 |
| Common shares issued in offering, net of issuance costs | 13,196,671 | 14 | 67,708 | — | — | 67,722 |
| Pre-funded warrants issued | — | — | 12,054 | — | — | 12,054 |
| Return of capital from a stockholder - related party | — | — | 689 | — | — | 689 |
| Other comprehensive income | — | — | — | 3,891 | — | 3,891 |
| Net loss | — | — | — | — | (101,744) | (101,744) |
| Balance at December 31, 2023 | 102,202,759 | $102 | $624,076 | $186 | $(371,256) | $253,108 |
| Issuance of common stock from exercise of options and employee stock purchase plan | 1,525,384 | 2 | 5,939 | — | — | 5,941 |
| Stock based compensation expense | — | — | 28,897 | — | — | 28,897 |
| Common shares issued in offering, net of issuance costs | 4,001,200 | 4 | 41,719 | — | — | 41,723 |
| Other comprehensive income | — | — | — | 150 | — | 150 |
| Net loss | — | — | — | — | (130,302) | (130,302) |
| Balance at December 31, 2024 | 107,729,343 | $108 | $700,631 | $336 | $(501,558) | $199,517 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.